

Personal Details

Name	Ulrich Ettinger
Place and date of birth	Nürtingen, Germany, 28 th April 1974
Nationality	German
Address	Department of Psychology University of Bonn Kaiser-Karl-Ring 9 53111 Bonn Germany
Email	ulrich.ettinger@uni-bonn.de
Phone	+ 49 228 734208

Present Position

Since 04/2012	Professor of Psychology Department of Psychology, University of Bonn, Bonn, Germany
Since 01/2009	Visiting Senior Lecturer Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

Previous Positions

01/2009 – 03/2012	DFG Emmy Noether Research Group Leader Department of Psychiatry and Department of Psychology, Ludwig-Maximilians- University, Munich, Germany
04/2011 – 03/2012	Locum Professor of Psychology (Vertretungsprofessur) Department of Psychology, University of Bonn, Germany
10/2004 – 12/2008	Research Fellow and Lecturer / Senior Lecturer Department of Neuroimaging, Institute of Psychiatry, King's College London, UK
10/2003 – 09/2004	Richard H. Tomlinson Postdoctoral Research Fellow Department of Psychology and Douglas Hospital, McGill University, Montreal, Canada
10/2002 – 09/2003	Postdoctoral Research Worker Division of Psychological Medicine, Institute of Psychiatry, King's College London, UK

University Education

01/2011	Habilitation (Venia Docendi) in Psychology Ludwig-Maximilians-University, Munich, Germany
09/1999 – 09/2002	PhD Department of Psychology, Goldsmiths College, and Division of Psychological Medicine, Institute of Psychiatry, King's College London, UK
10/1998 – 09/1999	MSc Neuroscience, passed with <i>Distinction</i> Institute of Psychiatry, King's College London, UK
09/1995 – 06/1998	BSc Psychology, passed with <i>1st Class Honours</i> Goldsmiths College, University of London, UK

Advisory, Editorial and Administrative Activities

Since 08/2007	Research grant review Action Medical Research (UK) Agence National de la Recherche (France) Chief Scientist Office, Scottish Government (UK) Deutsche Forschungsgemeinschaft (Germany) Deutscher Akademischer Austauschdienst (Germany) Dutch Organisation for Health Research and Development (ZonMw) (NL) Fondation FondaMental (France) Foundation for Science and Technology (Portugal) FWF (Austria) Inserm (France) Israel Science Foundation (Israel) Jubiläumsfonds der Österreichischen Nationalbank (Austria) Leopoldina National Academy of Science (Germany) Medical Research Council (UK) Medical Research Scotland (UK) Multiple Sclerosis Research Australia (Australia) The Royal Society (UK) Studienstiftung des deutschen Volkes (Germany) VolkswagenStiftung (Germany) Wellcome Trust (UK)
Since 10/2015	Editorial Board Member <i>Journal of Eye Movement Research</i>
Since 06/2015	Editorial Board Member <i>Journal of Affective Disorders</i>
Since 01/2014	Action Editor <i>Brain and Cognition</i>
Since 04/2013	Associate Editor <i>Frontiers in Psychiatry</i>

- 2013 **Member of the programme committee**
28th Symposium of the AGNP
- Since 04/2012 **Administrative activities, University of Bonn**
Department of Psychology: Ethics Committee, Teaching Quality Funding Committee
Faculty of Philosophy: BAföG-Administration, Exams Committee, PhD Committee, Tenure Track Committee, Infrastructure Committee, PROMOS Stipend Committee
- 11/2007 – 09/2009 **Member of the MSc Neuroscience programme committee and exam board**
Institute of Psychiatry, King's College London, UK
- 03/2007 – 12/2008 **Editor of special issue "A hundred years of eye movement research in psychiatry"**
Brain and Cognition
- 01/2005 – 01/2007 **Member of the scientific advisory board**
Human Brain Mapping conferences 2005-2007
- 07/2005 – 12/2008 **Member of the research ethics committee**
Institute of Psychiatry and SLaM NHS Trust, London, UK
- Since 2005 **External reviewer for academic appointments and promotions**
HSD Hochschule Döpfel, Cologne, Germany
University of Athens, Georgia, USA
University of Bedfordshire, UK
University of East London, UK
University of Sussex, UK
UMIT, Hall in Tirol, Austria
- Since 09/2000 **Ad hoc review of manuscripts**
Acta Neuropsychiatrica
Acta Psychiatrica Scandinavica
Acta Psychologica
Addiction Biology
Adolescent Health, Medicine and Therapeutics
AIMS Neuroscience
Alcohol and Alcoholism
American Journal of Psychiatry
Annals of General Psychiatry
Archives of General Psychiatry
Attention, Perception, & Psychophysics
Autism – Open Access
Autism Research
Behavior Genetics
Behavior Research Methods
Behavioral and Brain Functions
Behavioural Brain Research
Biological Psychiatry
Biological Psychology
Biomedical Genetics and Genomics
Bipolar Disorders
BMC Neurology
BMC Psychiatry

Brain
Brain and Behavior
Brain and Cognition
Brain Imaging and Behavior
Brain Research
Brain Structure and Function
British Journal of Psychiatry
British Journal of Psychology
Cerebral Cortex
Clinical Schizophrenia & Related Psychoses
CNS & Neurological Disorders - Drug Targets
CNS Spectrums
Cognitive, Affective, and Behavioral Neuroscience
Cognitive and Behavioral Neurology
Cognitive Neuropsychiatry
Cognitive Neuroscience
Comprehensive Psychiatry
Cortex
Epidemiology and Psychiatric Sciences
European Archives of Psychiatry and Clinical Neuroscience
European Journal of Clinical Nutrition
European Journal of Neuroscience
European Neuropsychopharmacology
European Psychiatry
Expert Opinion on Medical Diagnostics
Expert Review of Neurotherapeutics
Experimental Brain Research
Experimental Psychology
Frontiers in Human Neuroscience
Frontiers in Systems Neuroscience
Genome Medicine
Hippocampus
Human Brain Mapping
Human Psychopharmacology: Clinical & Experimental
International Journal of Developmental Neuroscience
International Journal of Psychology and Counseling
International Journal of Psychophysiology
JAMA Psychiatry
Journal of Abnormal Psychology
Journal of Addiction Research and Therapy
Journal of Advances in Schizophrenia and Brain Research
Journal of Affective Disorders
Journal of Anesthesia and Clinical Research
Journal of Child Psychology and Psychiatry
Journal of Clinical Psychiatry
Journal of Cognitive Neuroscience
Journal of Diabetes & Metabolism
Journal of Eye Movement Research
Journal of Forensic Sciences
Journal of Individual Differences
Journal of Neural Transmission
Journal of Neuroscience
Journal of Personality Disorders
Journal of Physiology
Journal of Psychiatry and Neuroscience
Journal of Psychopharmacology

Journal of Sport & Exercise Psychology
The Lancet Psychiatry
Nature and Science of Sleep
Neurobiology of Aging
Neurocase
NeuroImage
NeuroImage: Clinical
Neurological Research
Neuropsychiatric Disease and Treatment
Neuropsychologia
Neuropsychology
Neuropsychopharmacology
Neuroscience
Neuroscience & Biobehavioral Reviews
Neuroscience Letters
Nordic Journal of Psychiatry
The Open Psychiatry Journal
PeerJ
Personality and Individual Differences
PET and SPECT in Psychiatry (Springer Verlag)
Pharmaceuticals
Physiology & Behavior
Phytomedicine
PLoS ONE
Progress in Neuro-Psychopharmacology & Biological Psychiatry
Psychiatry Research
Psychological Assessment
Psychological Medicine
Psychological Research
Psychonomic Bulletin & Review
Psychopharmacology
Psychophysiology
Quarterly Journal of Experimental Psychology
Schizophrenia Bulletin
Schizophrenia Research
Scientific Reports
Substance Abuse Treatment, Prevention, and Policy
SUHT
Translational Psychiatry
Trends in Cognitive Sciences
Visual Cognition
World Journal of Biological Psychiatry
Yonsei Medical Journal

Awarded Grants

Deutsche Forschungsgemeinschaft (DFG), Research Grant (12/2015)

“Why do not all high schizotypes develop schizophrenia? Protective factors in people with high risk for schizophrenia using machine learning methods”

Ettinger U

€159,760

Deutsche Forschungsgemeinschaft (DFG), Research Grant (08/2014)

"Anxiety, Fear and Human Defensive Reactions: Behavioural Differentiation of Generalised Anxiety Disorder and Panic Disorder"

Ettinger U

€148,630

Boehringer Ingelheim Stiftung, Summer School (05/2014)

"European Summer School on Eye Movements (ESSEM) 2014"

Klein C, Ettinger U

€30,000

ElectroCore Medical LLC, Project Grant (04/2013)

"Effects of Acute Vagus Nerve Stimulation on Pupil Size in Healthy Humans"

Ettinger U

€5,935

VolkswagenStiftung, Summer School Grant (02/2013)

"European Summer School on Eye Movements"

Ettinger U, Klein C

€37,200

Friedrich-Baur-Stiftung, Research Grant (07/2010)

"Molecular Predictors of Brain Functional and Cognitive Response to Methylphenidate"

Ettinger U

€9,800

GE Healthcare, Research Grant (03/2010)

"The role of the dopamine transporter in frontal-striatal brain function"

Ettinger U (PI), la Fougère C (Co-PI)

€15,000

Deutsche Forschungsgemeinschaft (DFG), Emmy Noether Programm Supplementary Application (02/2010)

"Neuroimaging, pharmacological, and genetic studies of the oculomotor system in healthy and schizophrenic individuals"

Ettinger U

€61,319

Support Programme for Research and Teaching, Medical Faculty, University of Munich (Förderprogramm für Forschung und Lehre der Medizinischen Fakultät der LMU München) (12/2009)

"Heritability of Human Brain Function"

Ettinger U

€47,962

British Academy, Small Research Grant (12/2008)

"Personality and Reproductive Fitness"

Kumari V (PI), Ettinger U (Co-PI), Martin NG (Co-PI)

£7,316

Deutsche Forschungsgemeinschaft (DFG), Emmy Noether Programm (07/2008)

"Neuroimaging, pharmacological, and genetic studies of the oculomotor system in healthy and schizophrenic individuals"

Ettinger U

€1,100,000 (approx.)

Macular Disease Society, Research Grant (05/2008)

"Non-drug treatments for visual hallucinations"

ffytche D (PI), Zelaya F (Co-PI), Ettinger U (Co-PI), Deane C (Co-PI)
£37,950

P1vital Ltd., Research Grant (05/2008)

"Multicentre Consortium Studies: Translational Models of Psychiatric Disease"
Williams SC (PI), Ettinger U (Co-PI), Mitterschiffthaler MT (Co-PI), Barkus E (Co-PI), Morris R (Co-PI)
£550,001

British Academy, Conference Grant (03/2008)

Ettinger U
£200

The Guarantors of Brain, Conference Grant (02/2008)

Ettinger U
£650

National Institute for Health Research (England), Postdoctoral Fellowship (07/2007)

"Schizotypy as a marker of risk for schizophrenia"
Ettinger U
£356,040

British Council, Collaborative Travel Grant (with M. Wagner, University of Bonn, Germany) (06/2007)

"Nicotine effects on schizophrenia endophenotypes"
Ettinger U
£900

Royal Society, Conference Grant (08/2006)

Ettinger U
£800

The Guarantors of Brain, Conference Grant (12/2005)

Ettinger U
£760

Economic and Social Research Council (ESRC) and Medical Research Council (MRC), UK, Postdoctoral Research Fellowship (07/2004)

"Functional magnetic resonance imaging of nicotine effects on eye movements"
Ettinger U
£65,341

Leverhulme Trust, Early Career Fellowship (05/2004)

"Neuroimaging of nicotine effects on eye movements"
Ettinger U
£45,967

G.W. Stairs Memorial Fund, Research Grant (04/2004)

"Effects of Methylphenidate on Oculomotor Control as a Function of Dopamine Genes"
Ettinger U
CAD\$11,000

British Academy, Small Research Grant (05/2003)

"Eye movement deficits as markers of the genetic liability for schizophrenia"
Ettinger U
£4,995

British Academy, Conference Grant (05/2003)

Ettinger U
£168

Experimental Psychology Society, Grindley Grant (02/2003)

Ettinger U
£400

The Guarantors of Brain, Conference Grant (02/2003)

Ettinger U
£550

Richard H. Tomlinson Postdoctoral Research Fellowship (02/2003)

Ettinger U
"Dopamine D3 receptor gene, eye movements, and brain function in schizotypy"
CAD\$60,000

Royal Society, Conference Grant (01/2003)

Ettinger U
£260

British Psychological Society, Conference Grant (04/2001)

Ettinger U
£100

The Guarantors of Brain, Conference Grant (04/2001)

Ettinger U
£350

International Society for the Study of Individual Differences, Conference Grant (01/2001)

Ettinger U
£145

University of London Central Research Funds, Small Research Grant (12/2000)

"A Study into the Psychophysiology of Psychosis-Proneess"
Ettinger U
£1,500

Awards and Honours

Psychopharmacology Senior Non-Clinical Award, British Association for Psychopharmacology (06/2014)

Teaching Award, University of Bonn (06/2013)

Rafaelsen Award, Collegium Internationale Neuro-Psychopharmacologicum (03/2009)

Young Scientist Award, 14th Biennial Winter Workshop on Schizophrenia (11/2007)

Deutsche Gesellschaft für Biologische Psychiatrie Förderpreis (German Society for Biological Psychiatry Award) (08/2006)

Young Investigator Award, International Congress on Schizophrenia Research (02/2005)

Travel Award, Organisation for Human Brain Mapping (05/2004)

Young Scientist Award, 12th Biennial Winter Workshop on Schizophrenia (11/2003)

Young Scientist Award, 11th Biennial Winter Workshop on Schizophrenia (11/2001)

Bursary of the Department of Psychology (Goldsmiths College) for PhD (09/1999)

Studentship of the Section of Cognitive Psychopharmacology (Institute of Psychiatry) for PhD (09/1999)

Bursary of the Department of Neuroscience (Institute of Psychiatry) for MSc Neuroscience (10/1998)

Goldsmiths Psychology Prize for Best BSc in Psychology (09/1998)

Memberships of Professional Bodies

Associate Fellow of the British Psychological Society (BPS)

Berufsverband Deutscher Psychologen und Psychologinnen (BDP; Professional Association of German Psychologists)

Deutsche Gesellschaft für Psychologie (DGPs; German Society for Psychology)

Deutscher Hochschulverband (DHV; German University Association)

British Association for Psychopharmacology (BAP)

Publications

ResearcherID Citation Metrics:

Sum of the Times Cited: 3471

Average Citations per Article: 21.56

H-index: 29

Original Papers in Journals with Peer Review

1. Oberlader VA, **Ettinger U**, Banse R, Schmidt AF (in press). Development of a Cued Pro- and Antisaccade Paradigm: An Indirect Measure to Explore Automatic Components of Sexual Interest. Archives of Sexual Behavior.
2. Kasparbauer AM, Meyhöfer I, Steffens M, Weber B, Aydin M, Kumari V, Hurlemann R, **Ettinger U** (in press). Neural effects of methylphenidate and nicotine during smooth pursuit eye movements. NeuroImage.
3. Steffens M, Becker B, Neumann C, Kasparbauer AM, Meyhöfer I, Weber B, Mehta MA, Hurlemann R, **Ettinger U** (in press). Effects of Ketamine on Brain Function during Smooth Pursuit Eye Movements. Human Brain Mapping.

4. Talanow T, Kasparbauer AM, Steffens M, Meyhöfer I, Weber B, Smyrnis N, **Ettinger U** (in press). Facing Competition: Neural Mechanisms Underlying Parallel Programming of Antisaccades and Prosaccades. Brain & Cognition.
5. Antonova E, Amaratunga K, Wright B, **Ettinger U**, Kumari V (in press). Schizotypy and Mindfulness: Magical Thinking without Suspiciousness Characterises Mindfulness Meditators. Schizophrenia Research: Cognition.
6. Wright B, Peters E, **Ettinger U**, Kuipers E, Kumari V (in press). Moderators of Noise-induced Cognitive Change in Healthy Adults. Noise and Health.
7. Kambeitz J, la Fougère C, Werner N, Pogarell O, Riedel M, Falkai P, **Ettinger U** (in press). Nicotine-Dopamine-Transporter Interactions During Reward-Based Decision Making. European Neuropsychopharmacology.
8. Wright B, Peters E, **Ettinger U**, Kuipers E, Kumari V (in press). Effects of Environmental Noise on Cognitive (Dys)functions in Schizophrenia: A Pilot Within-Subjects Experimental Study. Schizophrenia Research.
9. Koychev I, Joyce D, Barkus E, **Ettinger U**, Schmechtig A, Dourish CT, Dawson GR, Craig KJ, Deakin JFW (in press). Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies. Translational Psychiatry.
10. Meyhöfer I, Bertsch K, Esser M, **Ettinger U** (in press). Variance in Saccadic Eye Movements Reflects Stable Traits. Psychophysiology.
11. Picchioni M, Touloupoulou T, Chaddock C, Cole J, **Ettinger U**, Oses A, Metcalfe H, Lombardi A, Lico C, Murray RM, McGuire P (in press). Familial and Unique Environmental Influences on Brain Volumes in Twins with Schizophrenia. Journal of Psychiatry and Neuroscience.
12. **Ettinger U**, Merten N, Kambeitz J (2016) Meta-analysis of the Association of the *SLC6A3* 3'-UTR VNTR with Cognition. Neuroscience & Biobehavioral Reviews, *60*, 72-81.
13. Polner B, Aichert D, Macare C, Costa A, **Ettinger U** (2015). Gently Restless: Association of ADHD-like Traits with Response Inhibition and Interference Control. European Archives of Psychiatry and Clinical Neuroscience, *265*(8), 689-699.
14. Kumari V, **Ettinger U**, Lee S, Deuschl C, Anilkumar A, Schmechtig A, Corr P, ffytche D, Williams S (2015). Common and Distinct Neural Effects of Risperidone and Olanzapine during Procedural Learning in Schizophrenia: A Randomised Longitudinal fMRI Study. Psychopharmacology, *232*(17), 3135-3134.
15. Schulze-Rauschenbach S, Lennertz L, Ruhrmann S, Petrovsky N, **Ettinger U**, Pukrop R, Dreher J, Klosterkötter J, Maier W, Wagner M (2015). Neurocognitive functioning in parents of schizophrenia patients: Attentional and executive performance vary with genetic loading. Psychiatry Research, *230*(3), 885-891.
16. Kasparbauer AM, Merten N, Aichert DS, Wöstmann N, Meindl T, Rujescu D, **Ettinger U** (2015). Association of *COMT* and *SLC6A3* Polymorphisms with Impulsivity, Response Inhibition and Brain Function. Cortex, *71*, 219-231.
17. Meyhöfer I, Steffens M, Kasparbauer A, Grant P, Weber B, **Ettinger U** (2015). Neural Mechanisms of Smooth Pursuit Eye Movements in Schizotypy. Human Brain Mapping, *36*(1), 340-353.
18. Kasparbauer AM, Rujescu D, Riedel M, Pogarell O, Costa A, Meindl T, la Fougère C, **Ettinger U** (2015). Methylphenidate Effects on Brain Activity as a Function of *SLC6A3* Genotype and Striatal Dopamine Transporter Availability. Neuropsychopharmacology, *40*(3), 736-745.

19. Herweg N, Weber B, Kasparbauer A, Meyhöfer I, Steffens M, Smyrnis N, **Ettinger U** (2014). Functional Magnetic Resonance Imaging of Sensorimotor Transformations in Saccades and Antisaccades. NeuroImage, *102*(Pt 2), 848-860.
20. Mueller S, Costa A, Keeser D, Pogarell O, Berman A, Coates U, Reiser MF, Riedel M, Möller HJ, **Ettinger U**, Meindl T (2014) The Effects of Methylphenidate on Whole Brain Intrinsic Functional Connectivity. Human Brain Mapping, *35*(11), 5379-5388.
21. Petrovsky N*, **Ettinger U***, Hill A, Frenzel L, Meyhöfer I, Wagner M, Backhaus J, Kumari V (2014). Sleep deprivation disrupts prepulse inhibition and induces psychosis-like symptoms in healthy humans. Journal of Neuroscience, *34*(27), 9134-9140. * shared first authorship
22. Macare C, Meindl T, Nenadic I, Rujescu D, **Ettinger U** (2014). Preliminary Findings on the Heritability of the Neural Correlates of Response Inhibition. Biological Psychology, *103*, 19-23.
23. Hamm JP, Crawford TJ, Nebl H, Kean M, Williams SCR, **Ettinger U** (2014). Neural correlates of illusory line motion. PLoS ONE, *9*(1):e87595. doi: 10.1371/journal.pone.0087595.
24. Kambeitz J, Romanos M, **Ettinger U** (2014). Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. The Pharmacogenomics Journal, *14*(1), 77-84.
25. Saville CWN, Lancaster TM, Stefanou ME, Salunkhe G, Lourmpa I, Nadkarni A, Boehm SG, Bender S, Smyrnis N, **Ettinger U**, Feige B, Biscaldi M, Mantripragada KK, Linden DEJ, Klein C (2014) COMT Val158Met genotype is associated with fluctuations in working memory performance: converging evidence from behavioural and single-trial P3b measures. NeuroImage, *100*, 489-497.
26. Cutsuridis V, Kumari V, **Ettinger U** (2014). Antisaccade Performance in Schizophrenia: A Neural Model of Decision Making in the Superior Colliculus. Frontiers in Decision Neuroscience, *8*:13, doi: 10.3389/fnins.2014.00013.
27. Petrovsky N, **Ettinger U**, Quednow BB, Landsberg MW, Drees J, Lennertz L, Frommann I, Heilmann K, Sträter B, Kessler H, Dahmen N, Mössner R, Maier W, Wagner M (2013). Nicotine enhances antisaccade performance in schizophrenia patients and healthy controls. International Journal of Neuropsychopharmacology, *16*(7), 1473-1481.
28. Petrovsky N, **Ettinger U**, Kessler H, Mössner R, Wolfsgruber S, Dahmen N, Maier W, Wagner M, Quednow BB (2013). The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism. Psychopharmacology, *229*(1), 31-40.
29. Perkins AM, Cserjesi R, **Ettinger U**, Kumari V, Martin NG, Arden R (2013). Personality and occupational markers of 'solid citizenship' are associated with having fewer children. Personality and Individual Differences, *55*(8), 871-876.
30. Perkins AM, Leonard A, Krueger K, Dalton J, Mehta MA, Kumari V, Williams SCR, **Ettinger U** (2013). A dose of ruthlessness: interpersonal moral judgment is hardened by the anti-anxiety drug lorazepam. Journal of Experimental Psychology: General. *142*(3), 612-20.
31. Perkins AM, **Ettinger U**, Weaver K, Schmechtig A, Schrantee A, Morrison PD, Sapara A, Kumari V, Williams SCR, Corr PK (2013). Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type. Translational Psychiatry, *3*, e246. doi: 10.1038/tp.2013.20.
32. Wöstmann NM, Aichert DS, Costa A, Rubia K, Möller HJ, **Ettinger U** (2013). Reliability and plasticity of response inhibition and interference control. Brain and Cognition, *81*(1), 82-94.

33. Aichert DS, Derntl B, Wöstmann NM, Groß JK, Dehning S, Cerovecki A, Möller HJ, Habel U, Riedel M, **Ettinger U** (2013). Intact emotion-cognition interaction in schizophrenia patients and first-degree relatives: Evidence from an emotional antisaccade task. *Brain and Cognition*, 82(3), 329-336.
34. Schmechtig A, Lees J, Perkins A, Altavilla A, Craig KJ, Dawson GR, Deakin JFW, Dourish CT, Evans LH, Koychev I, Weaver K, Smallman R, Walters J, Wilkinson LS, Morris R, Williams SCR, **Ettinger U** (2013). The Effects of Ketamine and Risperidone on Eye Movement Control in Healthy Volunteers. *Translational Psychiatry*. 3:e334. doi: 10.1038/tp.2013.109
35. **Ettinger U**, Corr PJ, Mofidi A, Williams SCR, Kumari V (2013). Dopaminergic basis of the psychosis-prone personality investigated with functional magnetic resonance imaging of procedural learning. *Frontiers in Human Neuroscience*, Vol 7, Article 130.
36. Schmechtig A, Lees J, Grayson L, Craig KJ, Dadhiwala R, Dawson GR, Deakin JFW, Dourish CT, Koychev I, McMullen K, Migo EM, Perry C, Wilkinson L, Morris R, Williams SCR, **Ettinger U** (2013). Effects of Risperidone, Amisulpride and Nicotine on Eye Movement Control and their Modulation by Schizotypy. *Psychopharmacology*, 227, 331-345.
37. Antoniadou C, **Ettinger U**, Gaymard B, Gilchrist I, Kristjansson A, Kennard C, Leigh J, Noorani I, Pouget P, Smyrnis N, Tarnowski A, Zee D, Carpenter RHS (2013). An internationally standardised antisaccade protocol for clinical use. *Vision Research*, 84, 1-5.
38. Segal NL, Graham J, **Ettinger U** (2013). Unrelated Look-Alikes: A Replicated Study of Personality Similarity and New Qualitative Findings on Social Relatedness. *Personality and Individual Differences*, 55, 169-174.
39. Costa A, Riedel M, Pogarell O, Menzel-Zelnitschek F, Schwarz M, Reiser M, Möller HJ, Rubia K, Meindl T, **Ettinger U** (2013). Methylphenidate effects on neural activity during response inhibition in healthy humans. *Cerebral Cortex*, 23, 1179-1189.
40. Costa A, la Fougere C, Pogarell O, Möller HJ, Riedel M, **Ettinger U** (2013). Impulsivity is related to striatal dopamine transporter availability in healthy males. *Psychiatry Research: Neuroimaging*, 211, 251-256.
41. Liepelt R, Schneider J, Aichert DS, Wöstmann N, Dehning S, Möller HJ, Riedel M, Dolk T, **Ettinger U** (2012). Action Blind: Disturbed Self-other Integration in Schizophrenia. *Neuropsychologia*, 50(14), 3775-3780.
42. Macare C, Bates TC, Heath AC, Martin NG, **Ettinger U** (2012). Substantial genetic overlap between schizotypy and neuroticism: A twin study. *Behavior Genetics*, 42(5), 732-742.
43. Aichert DS, Wöstmann NM, Costa A, Macare C, Wenig JR, Möller HJ, Rubia K, **Ettinger U** (2012). Associations between Trait Impulsivity and Prepotent Response Inhibition. *Journal of Experimental and Clinical Neuropsychology*, 34(10), 1016-1032.
44. Allman AA, **Ettinger U**, Joobar R, O'Driscoll GA (2012). Effects of methylphenidate on basic and higher-order oculomotor functions. *Journal of Psychopharmacology*, 26(11), 1471-1479.
45. Völter C, Strobach T, Aichert DS, Wöstmann N, Costa A, Möller HJ, Schubert T, **Ettinger U** (2012). Schizotypy and behavioural adjustment and the role of neuroticism. *PLoS ONE*, 7(2), e30078.
46. Völter C, Riedel M, Wöstmann N, Aichert D, Lobo S, Costa A, Schmechtig A, Collier DA, Hartmann AM, Giegling I, Möller HJ, Quednow BB, Rujescu D, Kumari V, **Ettinger U** (2012). Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach. *International Journal of Neuropsychopharmacology*, 15(10), 1427-1440.
47. Aichert DS, Williams SCR, Möller HJ, Kumari V, **Ettinger U** (2012). Functional neural correlates of psychometric schizotypy: an fMRI study of antisaccades. *Psychophysiology*, 49(3), 345-356.

48. **Ettinger U**, Williams SCR, Meisenzahl EM, Möller HJ, Kumari V, Koutsouleris N (2012). Association between brain structure and psychometric schizotypy in healthy individuals. World Journal of Biological Psychiatry, **13**(7), 544-549.
49. Petrovsky N, **Ettinger U**, Quednow BB, Walter H, Schnell K, Kessler H, Mössner R, Maier W, Wagner M (2012). Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy. Psychopharmacology, **221**(1), 27-38.
50. Premkumar P, **Ettinger U**, Inchley-Mort S, Sumich A, Williams SCR, Kuipers E, Kumari V (2012). Neural processing of social rejection: the role of schizotypal personality traits. Human Brain Mapping, **33**(3), 695-706.
51. Owens SF, Picchioni M, **Ettinger U**, McDonald C, Walshe M, Schmechtig A, Murray R, Rijdsdijk F, Touloupoulou T (2012). Prefrontal deviations in function but not volume are putative endophenotypes for schizophrenia. Brain, **135**(Pt 7), 2231-2244.
52. Koychev I, McMullen K, Lees J, Dadhiwala R, Perry C, Schmechtig A, Walters J, Craig KJ, Dawson GR, Dourish CT, **Ettinger U**, Wilkinson L, Williams S, Deakin JFW, Barkus E (2012). A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-centre double-blind placebo-controlled study. European Neuropsychopharmacology, **22**(7), 469-481.
53. **Ettinger U**, Schmechtig A, Touloupoulou T, Borg C, Orrells C, Owens S, Matsumoto K, van Haren NE, Hall MH, Kumari V, McGuire PK, Murray RM, Picchioni M (2012). Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. Schizophrenia Bulletin, **38**(1), 192-203.
54. **Ettinger U**, Williams SCR, Fannon D, Premkumar P, Kuipers E, Möller HJ, Kumari V (2011). Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. Psychopharmacology, **216**(1), 17-27.
55. Costa A, Riedel M, Müller U, Möller HJ, **Ettinger U** (2011). Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human SPECT studies. Synapse, **65**(10), 998-1005.
56. Quednow BB, **Ettinger U**, Mössner R, Rujescu D, Giegling I, Collier DA, Schmechtig A, Kühn KU, Möller HJ, Maier W, Wagner M, Kumari V (2011). The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. Journal of Neuroscience, **31**(18), 6684-6691.
57. Kempton MJ, Underwood TS, Brunton S, Stylios F, Schmechtig A, **Ettinger U**, Smith MS, Lovestone S, Crum WR, Frangou S, Williams SC, Simmons A (2011). A comprehensive testing protocol for neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method. NeuroImage, **58**(4), 1051-1059.
58. Perkins AM, **Ettinger U**, Williams SCR, Reuter M, Hennig J, Corr PJ (2011). Flight behaviour in humans is intensified by a candidate genetic risk factor for panic disorder: evidence from a translational model of fear and anxiety. Molecular Psychiatry, **16**(3), 242-244.
59. Kempton M*, **Ettinger U***, Foster R, Williams SCR, Calvert G, Hampshire A, Zelaya F, O’Gorman R, McMorris T, Owen AM, Smith M (2011). Dehydration affects brain structure and function in healthy adolescents. Human Brain Mapping, **32**(1), 71-79. * *shared first authorship*
60. Hall MH, Taylor G, Sham P, Schulze K, Rijdsdijk F, Picchioni M, Touloupoulou T, **Ettinger U**, Bramon E, Murray RM, Salisbury DF (2011). The early auditory gamma band response is heritable and a putative endophenotype of schizophrenia. Schizophrenia Bulletin, **37**(4), 778-787.

61. Schmechtig A, Vassos E, Kumari V, Hutton SB, Collier DA, Morris RG, Williams SCR, **Ettinger U** (2010). Association of *Neuregulin 1* rs3924999 genotype with antisaccades and smooth pursuit eye movements. *Genes, Brain and Behavior*, 9(6), 621-627.
62. Borgwardt SJ, Picchioni M, **Ettinger U**, Touloupoulou T, Murray R, McGuire PK (2010). Gray matter volume in monozygotic twins with schizophrenia – a voxel-based morphometry study. *Biological Psychiatry*, 67(10), 956-964.
63. Petrovsky N, Quednow BB, **Ettinger U**, Schmechtig A, Mössner R, Collier D, Kühn KU, Maier W, Wagner M, Kumari V (2010). Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. *Neuropsychopharmacology*, 35(7), 1429-1439.
64. Crawford TJ, Hamm JP, Kean M, Schmechtig A, Kumari V, Anilkumar AP, **Ettinger U** (2010). The perception of real and illusory motion in schizophrenia. *Neuropsychologia*, 48(10), 3121-3127.
65. Haraldsson HM, **Ettinger U**, Magnúsdóttir BB, Ingason A, Hutton SB, Sigmundsson T, Sigurdsson E, Petursson H (2010). Neuregulin-1 genotypes and eye movements in schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, 260(1), 77-85.
66. Haraldsson HM, **Ettinger U**, Magnúsdóttir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H (2010). Catechol-O-methyltransferase Val 158 Met polymorphism and antisaccade eye movements in schizophrenia. *Schizophrenia Bulletin*, 36(1), 157-164.
67. Perkins AM, **Ettinger U**, Davis R, Foster R, Williams SCR, Corr PJ (2009). Effects of lorazepam and citalopram on human defensive reactions: ethopharmacological differentiation of fear and anxiety. *Journal of Neuroscience*, 29(40), 12617-12624.
68. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnúsdóttir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdóttir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemény LA; Genetic Risk and Outcome in Psychosis (GROUP), Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, **Ettinger U**, Picchioni M, Walker N, Touloupoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA (2009). Common variants conferring risk of schizophrenia. *Nature*, 460(7256), 744-747.
69. Quednow BB, Schmechtig A, **Ettinger U**, Petrovsky N, Collier DA, Vollenweider FX, Wagner M, Kumari V (2009). Sensorimotor gating depends on polymorphisms of the 5-HT_{2A} receptor and COMT, but not on neuregulin-1 Arg38Gln genotype: a replication study. *Biological Psychiatry*, 66(6), 614-620.
70. **Ettinger U**, Williams SCR, Patel D, Michel TM, Nwaigwe M, Caceres A, Mehta M, Anilkumar AP, Kumari V (2009). Effects of acute nicotine on brain function in healthy smokers and non-smokers: estimation of inter-individual response heterogeneity. *NeuroImage*, 45, 549-561.
71. Petrovsky N, Schmechtig A, Flomen RH, Kumari V, Collier D, Makoff A, Wagner M, **Ettinger U** (2009). CHRFAM7A copy number and 2bp deletion polymorphisms and antisaccade performance. *International Journal of Neuropsychopharmacology*, 12, 267-273.
72. Haraldsson HM, **Ettinger U**, Magnúsdóttir BB, Sigmundsson T, Sigurdsson E, Ingason A, Petursson H (2009). COMT val158met genotype and smooth pursuit eye movements in schizophrenia. *Psychiatry Research*, 169, 173-175.

73. Hardoon D, **Ettinger U**, Mourao-Miranda J, Antonova E, Collier D, Kumari V, Williams SCR, Brammer M (2009). Correlation based multivariate analysis of genetic influence on brain volume. Neuroscience Letters, *450*, 281-286.
74. Petrovsky N, Weiss-Motz F, Schulze-Rauschenbach S, Lemke M, Hornung P, Ruhrmann S, Klosterkötter J, Maier W, **Ettinger U**, Wagner M (2009). Antisaccade performance is related to genetic loading for schizophrenia. Journal of Psychiatric Research, *43*, 291-297.
75. Kempton MJ, **Ettinger U**, Schmechtig A, Winter EM, Smith L, McMorris T, Wilkinson I, Williams SCR, Smith M (2009). Effects of acute dehydration on brain morphology in healthy humans. Human Brain Mapping, *30*, 291-298.
76. Rujescu D, Ingason A, Cichon S, Pietiläinen OPH, Barnes M, Toulopoulou T, Picchioni M, Vassos E, **Ettinger U**, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann A, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Andreassen OA, Djurovic S, Hansen T, Werge T, Melle I, Kiemenev LA, Franke B, Buizer-Voskamp JE, Ophoff R, GROUP Investigators, Rietschel M, Noethen M, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier D (2009). Disruption of the neurexin 1 gene is associated with schizophrenia. Human Molecular Genetics, *18*, 988-996.
77. **Ettinger U**, Kumari V, Collier DA, Powell J, Luzi S, Michel TM, Zedomi O, Williams SCR (2008). Catechol-O-methyltransferase (COMT) val¹⁵⁸met genotype is associated with brain activation as a function of task characteristic. Neuropsychopharmacology, *33*, 3046-3057.
78. Haraldsson HM, **Ettinger U**, Magnúsdóttir BB, Sigmundsson T, Sigurdsson E, Petursson H (2008). Eye movement deficits in schizophrenia: investigation of a genetically homogenous Icelandic sample. European Archives of Psychiatry and Clinical Neuroscience, *258*, 373-383.
79. Kempton MJ, Geddes JR, **Ettinger U**, Williams SCR, Grasby PM (2008). Meta-analysis, database and meta-regression of 98 structural imaging studies in bipolar disorder. Archives of General Psychiatry, *65*, 1017-1032.
80. Sumich A, Kumari V, Dodd P, **Ettinger U**, Hughes C, Zachariah E, Sharma T (2008). N100 and P300 amplitude to Go and No-Go variants of the auditory oddball in siblings discordant for schizophrenia. Schizophrenia Research, *98*, 265-277.
81. **Ettinger U**, ffytche DH, Kumari V, Kathmann N, Reuter B, Zelaya F, Williams SCR (2008). Decomposing the neural correlates of antisaccade eye movements using event-related fMRI. Cerebral Cortex, *18*, 1148-1159.
82. **Ettinger U**, Picchioni M, Landau S, Matsumoto K, Van Haren N, Marshall N, Hall MH, Schulze K, Toulopoulou T, Davies N, Ribchester T, McGuire PK, Murray RM (2007). Magnetic resonance imaging of the thalamus and adhesio interthalamica in twins with schizophrenia. Archives of General Psychiatry, *64*, 401-409.
83. Toulopoulou T, Picchioni M, Rijdsdijk F, Hall MH, **Ettinger U**, Sham P, Murray R (2007). Substantial genetic overlap between neurocognition and schizophrenia: genetic modelling in twin samples. Archives of General Psychiatry, *64*, 1348-1355.
84. Hall MH, Rijdsdijk F, Picchioni M, Schulze K, **Ettinger U**, Toulopoulou T, Bramon E, Murray RM, Sham P (2007). Substantial shared genetic influences on schizophrenia and event-related potentials. American Journal of Psychiatry, *164*, 804-812.

85. **Ettinger U**, Picchioni M, Hall MH, Schulze K, Touloupoulou T, Landau S, Crawford TJ, Murray RM (2006). Antisaccade performance in monozygotic twins discordant for schizophrenia: The Maudsley twin study. *American Journal of Psychiatry*, **163**, 543-545.
86. **Ettinger U**, Joober R, De Guzman R, O'Driscoll GA (2006). Schizotypy, attention deficit hyperactivity disorder features, and dopamine genes. *Psychiatry and Clinical Neurosciences*, **60**, 764-767.
87. Hall MH, Schulze K, Rijdsdijk F, Picchioni M, **Ettinger U**, Bramon E, Freedman R, Murray RM, Sham P (2006). Heritability and reliability of P300, P50 and duration mismatch negativity. *Behavior Genetics*, **36(6)**, 845-857.
88. **Ettinger U**, Hejda S, Flak V, Corr PJ (2005). Prepulse inhibition of the acoustic startle reflex and oculomotor control. *Psychophysiology*, **42(4)**, 473-482.
89. **Ettinger U**, Antonova E, Crawford TJ, Mitterschiffthaler MT, Goswami S, Sharma T, Kumari V (2005). Structural neural correlates of antisaccade and prosaccade eye movements in healthy humans. *NeuroImage*, **24**, 487-494.
90. **Ettinger U**, Kumari V, Crawford TJ, Flak V, Sharma T, Davis RE, Corr PJ (2005). Saccadic eye movements, schizotypy, and the role of neuroticism. *Biological Psychology*, **68(1)**, 61-78.
91. Kumari V, Das M, Zachariah E, **Ettinger U**, Sharma T (2005). Reduced prepulse inhibition in unaffected siblings of schizophrenia patients. *Psychophysiology* **42**, 588-594.
92. Kumari V, Antonova E, Zachariah E, Galea A, Aasen I, **Ettinger U**, Mitterschiffthaler MT, Sharma T (2005). Structural brain correlates of prepulse inhibition of the acoustic startle response in healthy humans. *NeuroImage* **26**, 1052-1058.
93. Hughes C, Kumari V, Das M, Zachariah E, **Ettinger U**, Sumich A, Sharma T (2005). Cognitive functioning in siblings discordant for schizophrenia. *Acta Psychiatrica Scandinavica*, **111(3)**, 185-192.
94. Kumari V, **Ettinger U**, Crawford TJ, Zachariah E, Sharma T (2005). Lack of association between prepulse inhibition and antisaccadic deficits in chronic schizophrenia: Implications for identification of schizophrenia endophenotypes. *Journal of Psychiatric Research*, **39**, 227-240.
95. **Ettinger U**, Kumari V, Chitnis XA, Corr PJ, Crawford TJ, Fannon DG, O'Ceallaigh S, Sumich AL, Doku V, Sharma T (2004). Volumetric neural correlates of antisaccade eye movements in first-episode psychosis. *American Journal of Psychiatry*, **161**, 1918-1921.
96. **Ettinger U**, Kumari V, Crawford TJ, Corr PJ, Das M, Hughes C, Sumich AL, Zachariah E, Rabe-Hesketh S, Sharma T (2004). Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia. *Journal of Psychiatric Research*, **38**, 177-184.
97. Das M, Kumari V, Soni W, **Ettinger U**, Binneman B, Hughes C, Mehrotra R, Sharma T (2004). Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia. *Schizophrenia Bulletin*, **30(2)**, 241-253.
98. **Ettinger U**, Kumari V, Zachariah E, Galea A, Crawford TJ, Corr PJ, Taylor D, Das M, Sharma T (2003). Effects of procyclidine on eye movements in schizophrenia. *Neuropsychopharmacology*, **28**, 2199-2208.
99. **Ettinger U**, Kumari V, Crawford TJ, Davis RE, Sharma T, Corr PJ (2003). Reliability of smooth pursuit, fixation, and saccadic eye movements. *Psychophysiology*, **40**, 620-628.
100. **Ettinger U**, Kumari V, Chitnis XA, Corr PJ, Sumich AL, Rabe-Hesketh S, Crawford TJ, Sharma T (2002). Relationship between brain structure and saccadic eye movements in healthy humans. *Neuroscience Letters*, **328(3)**, 225-228.

101. **Ettinger U**, Corr PJ (2001). The Frequency Accrual Speed Test (FAST): Psychometric intelligence and personality correlates. European Journal of Personality, **15**(2), 143-152.
102. **Ettinger U**, Chitnis XA, Kumari V, Fannon DG, Sumich AL, O’Ceallaigh S, Doku V, Sharma T (2001). Magnetic resonance imaging of the thalamus in first-episode psychosis. American Journal of Psychiatry, **158**(1), 116-118.

Review Articles in Journals with Peer Review

103. **Ettinger U**, Kumari V (2015). Effects of Sleep Deprivation on Inhibitory Biomarkers of Schizophrenia: Implications for Drug Development. Lancet Psychiatry, **2**(11), 1028-1035.
104. **Ettinger U**, Mohr C, Gooding DC, Cohen AS, Rapp A, Haenschel C, Park S (2015). Cognition and Brain Function in Schizotypy: A Selective Review. Schizophrenia Bulletin, **41**, S417-S426.
105. Cohen AS, Park S, Mohr C, **Ettinger U**, Chan R (2015). Schizotypy as an organizing framework for social and affective sciences. Schizophrenia Bulletin, **41**, S427-S435.
106. Mohr C, **Ettinger U** (2014). An Overview of the Association between Schizotypy and Dopamine. Frontiers in Psychiatry, **5**(184), 1-13.
107. Wright B, Peters E, **Ettinger U**, Kuipers E, Kumari V (2014). Understanding Noise Stress-Induced Cognitive Impairment and Its Implications for Schizophrenia. Noise & Health, **16**(70), 166-176.
108. **Ettinger U**, Meyhöfer I, Steffens M, Wagner M, Koutsouleris N (2014). Genetics, Cognition and Neurobiology of Schizotypal Personality: A Review of the Overlap with Schizophrenia. Frontiers in Psychiatry. 5:18.
109. Koychev I, Barkus E, **Ettinger U**, Killcross S, Roiser J, Wilkinson L, Deakin JFW (2011) Evaluation of state and trait biomarkers in healthy volunteers for new drug treatments in schizophrenia. Journal of Psychopharmacology, **25**, 1207-1225.
110. Haraldsson HM, **Ettinger U**, Sigurdsson E (2011). Developments in schizophrenia genetics: from linkage to microchips, deletions and duplications. Nordic Journal of Psychiatry, **65**(2), 82-88.
111. Hutton SB, **Ettinger U** (2006). The antisaccade task as a research tool in psychopathology: A critical review. Psychophysiology, **43**, 302-313.
112. Mitterschiffthaler MT, **Ettinger U**, Mehta MA, Mataix-Cols D, Williams SCR (2006). Applications of functional magnetic resonance imaging in psychiatry. Journal of Magnetic Resonance Imaging, **23**, 851-861.
113. **Ettinger U**, Kumari V (2003). Pharmacological studies of smooth pursuit and antisaccade eye movements in schizophrenia: current status and directions for future research. Current Neuropharmacology, **1**(4), 285-300.

Other Publications

114. **Ettinger U** (in press). Gehirn und Geist. Chapter in Kühnhardt L, Mayer T (Ed.), Bonner Enzyklopädie der Globalität.
115. **Ettinger U**, Klein C (in press). Eye Movements. Chapter in Reuter M, Montag C (Ed.), Neuroeconomics, Berlin: Springer Verlag.

116. Mohr C, **Ettinger U** (2015). The role of dopamine in schizotypy. Chapter in Mason O, Claridge G (Ed.), Schizotypy: New Dimensions, London and New York: Routledge, pp. 33-47.
117. Migo E, Williams SCR, Crum W, Kempton M, **Ettinger U** (2011). The role of neuroimaging biomarkers in personalised medicine for neuro-degenerative and psychiatric disorders. Chapter 3 in Gordon E, Koslow SH (Ed.), Integrative Neuroscience and Personalized Medicine, Oxford University Press, pp. 141-163.
118. Kumari V, **Ettinger U** (2010). Latent inhibition in schizophrenia and schizotypy: a review of the empirical literature. Chapter 17 in Lubow R, Weiner I (Ed.), Latent Inhibition: Cognition, Neuroscience, and Applications to Schizophrenia, Cambridge University Press, pp. 419-447.
119. Klein C, **Ettinger U** (2008). A hundred years of eye movement research in psychiatry. Brain and Cognition, **68**, 215-218. (Editorial)
120. Kumari V, **Ettinger U** (2005). Prepulse inhibition deficits in schizophrenia: Static or amenable to treatment? Chapter 6 in Lang MV (Ed.), Trends in Schizophrenia Research, Nova Science Publishers, pp. 95-117.
121. **Ettinger U** (2002). Review of the 11th World Congress of Psychophysiology. Journal of Advances in Schizophrenia and Brain Research, **4(4)**, 146-147.

Oral Presentations

1. *The Dopamine Transporter: From Molecular Imaging and Pharmacology to Cognition and Clinical Symptoms*. Invited speaker, Department of Psychology, University of Düsseldorf, Düsseldorf, Germany, July 2016
2. *Die Schizotypie: Ein Phänotyp im Spektrum der Schizophrenie (Schizotypy: A Phenotype of the Schizophrenia Spectrum)*. Invited speaker, Qualitätszirkel Bergisch Gladbach, Germany, June 2016
3. *The Role of the Dopamine Transporter in Cognition*. Invited speaker, Department of Psychology, German Sport University, Cologne, Germany, June 2016
4. *The Dopamine Transporter: From Molecular Imaging and Pharmacology to Cognition and Clinical Symptoms*. Invited speaker, Department of Psychotherapy, Martin-Luther-University Halle-Wittenberg, Halle, Germany, May 2016
5. *The Dopamine Transporter: From Molecular Imaging and Pharmacology to Cognition and Clinical Symptoms*. Tagung experimentell arbeitender Psychologen (TeaP), Heidelberg, Germany, March 2016
6. *Neuroenhancement*. Invited speaker, Institute of Science and Ethics, University of Bonn, January 2016
7. *Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality*. Invited speaker, Department of Psychology, University of Edinburgh, UK, September 2015
8. *"Found in Translation": Modellsysteme der Schizophrenie – Ketamin, Schlafentzug und Schizotypie (Model systems of schizophrenia – ketamine, sleep deprivation and schizotypy)*. Invited speaker, Universitäre Psychiatrische Kliniken Basel, Switzerland, February 2015

9. *Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia?* Invited speaker, Department of Psychology, City University, London, UK, February 2015
10. *Schlafentzug induziert Defizite in der Präpulsinhibition und Psychose-ähnliche Symptome (Sleep deprivation induces PPI deficits and psychosis-like symptoms)*. Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM), Cologne, Germany, December 2014
11. *"The Drugs Don't Work" – Eye Movements as Biomarkers in Psychopharmacology*. European Summer School on Eye Movements, Freiburg, Germany, September 2014
12. *Are Endophenotypes the End of Phenotypes?* European Summer School on Eye Movements, Freiburg, Germany, September 2014
13. *Human Model Systems of Schizophrenia*. British Association for Psychopharmacology, Cambridge, UK, July 2014
14. *Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia?* Invited speaker, Department of Psychiatry and Psychotherapy, University of Marburg, Marburg, Germany, December 2013
15. *Biological Approaches to Schizotypy: Evidence of a Continuum with Schizophrenia?* Plenary Lecture, Lemanic Workshop on Schizotypy, Geneva, Switzerland, December 2013
16. *Pharmacological Influences on Inhibitory Control*. Invited speaker, Research Centre Jülich, Jülich, Germany, November 2013
17. *Die Rolle der Okulomotorik in der Kognitionsforschung (The Role of Eye Movements in Cognition Research)*. Invited speaker, Centre for Economics and Neuroscience, University of Bonn, Bonn, Germany, November 2013
18. *Oculomotor Endophenotypes*. European Summer School on Eye Movements, Bonn, Germany, September 2013
19. *Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia?* Invited speaker, Department of Psychiatry, National University, Athens, Greece, March 2013
20. *Neuroimaging, Cognitive and Pharmacological Studies of Schizotypal Personality: Evidence of a Continuum with Schizophrenia?* Robert Sommer Award Symposium, Gießen, Germany, February 2013
21. *Cognitive and Neural Effects of Acute Methylphenidate in Healthy Humans*. DGPPN, Berlin, Germany, November 2012
22. *Effects of Nicotine and Antipsychotics on Cognitive Control: The Role of Schizotypy*. DGPPN, Berlin, Germany, November 2012
23. *Neurocognitive Studies of Intra-subject Variability*. 48. Kongress der Deutschen Gesellschaft für Psychologie, Bielefeld, Germany, September 2012
24. *Effects of Risperidone, Amisulpride and Nicotine on Antisaccade Eye Movements and their Modulation by Schizotypy*. 48. Kongress der Deutschen Gesellschaft für Psychologie, Bielefeld, Germany, September 2012
25. *fMRI Ergebnisse zur Neurokognition schizophrener Erkrankungen (fMRI Results on Neurocognition in Schizophrenia)*. Festschrift Symposium for Prof H.-J. Möller, University of Munich, Germany, July 2012

26. *Neural Mechanisms of Cognitive Enhancement*. Invited speaker, Bonner Imaging Seminar, University of Bonn, May 2012
27. *Neurocognitive Approaches to Schizotypal Personality*. Invited speaker, Department of Epileptology, University of Bonn, May 2012
28. *Pharmacological Influences on Oculomotor Control in Healthy Humans*. Vision Sciences Society, Naples, USA, May 2012
29. *Neurocognitive Mechanisms of Inhibitory Control*. TeaP, Mannheim, Germany, April 2012
30. *DFG Emmy Noether-Programm: Erfahrungsbericht*. Workshop "Forschen in Europa: Nationale und europäische Forschungsförderung", LMU München, March 2012
31. *The Study of Oculomotor Control: Taking a Close Look at Cognition and Brain (Dys-)Function*. Invited speaker, Department of Psychiatry, University of Bonn, Germany, February 2012
32. *Neurocognitive Approaches to Schizotypal Personality*. Invited speaker, Department of Psychiatry, University of Erlangen-Nuremberg, Germany, February 2012
33. *Effects of Methylphenidate on Cognition and Brain Function*. Invited speaker, Institute of Psychiatry, London, UK, January 2012
34. *Neurokognitive Untersuchungen der Schizotypie (Neurocognitive investigations of schizotypy)*. Invited speaker, Department of Psychiatry, University of Munich, Germany, January 2012
35. *Neurokognitive Mechanismen der Inhibitionsfähigkeit (Neurocognitive Mechanisms of Inhibitory Control)*. Invited speaker, Institut für Psychologie, Humboldt-Universität zu Berlin, Berlin, Germany, November 2011
36. *Methylphenidate Effects on Neural Activity during Response Inhibition in Healthy Humans*. AGNP Tagung, Munich, Germany, October 2011
37. *Neurokognitive Untersuchungen schizotyper Persönlichkeit (Neurocognitive investigations of schizotypal personality)*. Festschrift Symposium for Professor Rolf Engel, University of Munich, Germany, October 2011
38. *Die Rolle des Neurotizismus in der Assoziation zwischen Schizotypie und Kognition (The role of neuroticism in the association between schizotypy and cognition)*. DPPD Fachgruppentagung, Saarbrücken, Germany, September 2011
39. *Genetic and Neuroimaging Studies of Antisaccades in the Schizophrenia Spectrum*. European Conference on Eye Movements, Marseille, France, August 2011
40. *Biological Approaches to the Study of Schizotypal Personality*. Conference of the International Society for the Study of Individual Differences, London, UK, July 2011
41. *Neurokognitive Untersuchungen der Schizotypie (Neurocognitive Investigations of Schizotypy)*. Invited speaker, Department of Psychiatry, University of Ulm, Germany, July 2011
42. *Einfluss von Methylphenidat auf die neuronalen Korrelate der Inhibitionsfähigkeit (Effects of methylphenidate on the neural correlates of inhibitory control)*. Tagung Psychologie & Gehirn, Heidelberg, Germany, June 2011

43. *Auswirkungen von Methylphenidat auf die Okulomotorik bei gesunden Probanden (Effects of methylphenidate on oculomotor control in healthy subjects)*. Tagung Psychologie & Gehirn, Heidelberg, Germany, June 2011
44. *Neurobiological Approaches to the Study of Schizotypal Personality*. Invited speaker, Department of Psychiatry, University of Magdeburg, Germany, May 2011
45. *Neurocognitive Approaches to the Study of Schizotypal Personality*. Invited speaker, Department of Psychology, University of East London, UK, April 2011
46. *Einsatz von Stimulanzien: Neurobiologische Effekte (Neurobiological effects of stimulants)*. EEG-Tage, Munich, Germany, February 2011
47. *Methylphenidat: Auswirkungen auf Kognition und Gehirnfunktion (Methylphenidate: Effects on Cognition and Brain Function)*. Invited speaker, Department of Child and Adolescent Psychiatry, University of Freiburg, Germany, January 2011
48. *Genetic Studies of Neurophysiological Phenotypes in Schizophrenia*. DGPPN, Berlin, Germany, November 2010
49. *Functional Magnetic Resonance Imaging of a Parametric Working Memory Task in Schizophrenia: Relationship with Performance and Effects of Antipsychotic Treatment*. DGPPN, Berlin, Germany, November 2010
50. *Genetic and neuroimaging studies of eye movements*. Symposium on Clinical Neurophysiology of Vision and on Eye Movements, Ljubljana, Slovenia, September 2010
51. *Behavioural and Molecular Genetic Studies of Cognitive and Oculomotor Phenotypes*. Invited speaker, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany, June 2010
52. *Molecular and behavioural genetic studies of oculomotor, cognitive and neuroimaging phenotypes*. Invited speaker, Department of Psychology, University of Giessen, Giessen, Germany June 2010
53. *Okulomotorische Endophänotypen der Schizophrenie (Oculomotor endophenotypes of schizophrenia)*. Tagung Psychologie und Gehirn, Greifswald, Germany, June 2010
54. *Endophänotypen der Schizophrenie: Okulomotorik und Neuroimaging (Schizophrenia endophenotypes: eye movements and neuroimaging)*. Invited speaker, Department of Psychiatry, University of Basel, Switzerland, March 2010
55. *Neurobiologische Effekte von Methylphenidat bei Gesunden und Patienten (Neurobiological effects of methylphenidate in healthy people and patients)*, EEG-Tage, Munich, Germany, February 2010
56. *Oculomotor (Endo-)Phenotypes and Biomarkers*. Invited speaker, Institut für Medizinische Psychologie, Ludwig-Maximilians-Universität, Munich, Germany, January 2010
57. *Are endophenotypes the end of phenotypes?* Cognitive Neuropsychiatry Conference, Bremen, Germany, November 2009
58. *Effects of acute nicotine on brain function in healthy smokers and non-smokers: Estimation of inter-individual response heterogeneity*. AGNP Tagung, Munich, Germany, October 2009
59. *Eye movements in schizophrenia: Recent evidence from genetics and neuroimaging*. Plenary Lecture, British Ocular Motor Group Annual Meeting, Liverpool, UK, January 2009

60. *The role of psychology in brain science*. Invited speaker, Wycombe Abbey School, High Wycombe, UK, December 2008
61. *Imaging and oculomotor endophenotypes of schizophrenia*. Invited speaker, Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, London, UK, October 2008
62. *Psychophysiologische und bildgebende Endophänotypen der Schizophrenie*. Invited speaker, Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Göttingen, Germany, October 2008
63. *Effects of nicotine on brain function during saccadic eye movements*. XXVI CINP Congress, Munich, Germany, July 2008
64. *Imaging and pharmacological studies of oculomotor inhibition*. 16th European Congress of Psychiatry, Nice, France, April 2008
65. *Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia*. 16th European Congress of Psychiatry, Nice, France, April 2008
66. *Psychology careers*. Invited speaker, John Hampden Grammar School, High Wycombe, UK, March 2008
67. *Genetic and neuroimaging studies of oculomotor endophenotypes in schizophrenia*. Invited speaker, Klinik für Psychiatrie und Psychotherapie, RWTH Aachen, Aachen, Germany, January 2008
68. *Genetic and neuroimaging studies of oculomotor endophenotypes in schizophrenia*. Invited speaker, Institut für Psychologie, Universität Würzburg, Würzburg, Germany, January 2008
69. *Genetic and brain imaging studies of schizophrenia – the role of psychology*. Invited speaker, Eton College Psychological Society, Eton, UK, October 2007
70. *Genetic and Neuroimaging Studies of Oculomotor Endophenotypes*. 1st European Conference on Schizophrenia Research, Düsseldorf, Germany, September 2007
71. *Genetic and neuroimaging studies of eye movements in schizophrenia*. Invited speaker, Kneesworth House Hospital, Royston, UK, May 2007
72. *Einfluss von Nikotin auf Hirnaktivierung während einer okulomotorischen Arbeitsgedächtnisaufgabe bei gesunden Männern (Effects of nicotine on brain activation during an oculomotor working memory task in healthy men)*. Tagung experimentell arbeitender Psychologen (TeaP), Trier, Germany, March 2007
73. *Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia*. Invited speaker, School of Psychology, Birkbeck College, London, UK, March 2007
74. *Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia*. Invited speaker, Department of Psychology, University of Wales, Bangor, UK, March 2007
75. *Look away! Genetic and neuroimaging studies of antisaccade eye movements in schizophrenia*. Invited speaker, Neuroimaging Meeting, Institute of Psychiatry, London, February 2007
76. *Careers for Psychology PhD's: Academia & Beyond*. Panel discussant, Higher Education Academy Psychology Network. Southbank University, London, December 2006
77. *Relationship between prepulse inhibition and oculomotor control in schizophrenia*. Cognitive Neuropsychiatry Congress, Bremen, Germany, December 2006
78. *Look Away! Genetic and neuroimaging studies of antisaccade eye movements*. Invited speaker, Institut für Psychologie, Ludwig-Maximilians-Universität, Munich, Germany, November 2006

79. *Response inhibition and generation in the antisaccade task: an event-related fMRI study*. Society for Psychophysiological Research, Vancouver, Canada, October 2006
80. *Magnetic resonance imaging of the thalamus and adhesio interthalamica in twins with schizophrenia*. Deutsche Gesellschaft für Biologische Psychiatrie, Munich, Germany, October 2006
81. *Oculomotor deficits as endophenotypes for schizophrenia*. Invited speaker, Klinik für Psychiatrie, Universität Bonn, Germany, March 2006
82. *Antisakkadendefizite bei Schizophrenie (Antisaccade deficits in schizophrenia)*. Tagung Experimentell Arbeitender Psychologen (TeaP), Mainz, Germany, March 2006
83. *Antisakkadendefizite bei Angehörigen und Zwillingen von Schizophrenen (Antisaccade deficits in relatives and co-twins of people with schizophrenia)*. Deutsche Gesellschaft für Psychiatrie, Psychotherapie, und Nervenheilkunde Congress, Berlin, Germany, November 2005
84. *Taking a close look at schizophrenia: Genetic, pharmacological and neuroimaging studies of antisaccade eye movements*. Invited speaker, Department of Psychology, University of Wales, Swansea, UK, October 2005
85. *Taking a close look at schizophrenia: Genetic, pharmacological and neuroimaging studies of antisaccade eye movements*. Invited speaker, Department of Psychology, Thames Valley University, London, UK, March 2005
86. *Taking a close look at schizophrenia: Eye movement tasks as tools in genetic, pharmacological and neuroimaging studies*. Invited speaker, Max-Planck-Institut für Hirnforschung, Frankfurt, Germany, June 2004
87. *Antisaccades, schizotypy, and the role of neuroticism*. 11th Biennial Meeting of the International Society for the Study of Individual Differences, Graz, Austria, July 2003
88. *Eye movement endophenotypes in genetic and pharmacological studies of schizophrenia*. Invited speaker, Broadmoor Hospital, Crowthorne, UK, July 2003
89. *Eye movements in schizophrenia: Current status and directions for future research*. Invited speaker, Institut für Psychologie, Humboldt-Universität zu Berlin, Berlin, Germany, July 2003
90. *Eye movements in schizophrenia: Current status and directions for future research*. Invited speaker, Klinik für Neurologie II, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany, July 2003
91. *Eye movements in schizophrenia: Current status and directions for future research*. Invited speaker, Affective Neuroscience Group, Department of Psychology, Goldsmiths College, London, UK, May 2003
92. *Eye movements as schizophrenia endophenotypes*. Invited speaker, Division of Psychiatry, Landspítali University Hospital, Reykjavik, Iceland, November 2002
93. *Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia*. Invited speaker, Departement de Psychiatrie Générale, Université de Lille II, Lille, France, June 2002
94. *Smooth pursuit and antisaccade eye movements in siblings discordant for schizophrenia*. Invited speaker, Psychosis Interest Group, Institute of Psychiatry, London, UK, May 2002
95. *Eye movements and the genetics of schizophrenia*. Invited speaker, Department of Clinical Psychology, Northwick Park Hospital, London, UK, March 2002

96. *Neural correlates of saccadic eye movements in first-episode psychosis*. 13th Annual Meeting of the British Ocular Motor Group, Imperial College, London, UK, December 2001
98. *First-episode psychosis, magnetic resonance imaging, and saccadic eye movements*. Section of Cognitive Psychopharmacology Symposium, Institute of Psychiatry, London, UK, April 2001
99. *Structural MRI correlates of saccade and antisaccade performance in healthy and schizophrenic subjects*. The First Irish Workshop on Eye-Tracking, Trinity College Dublin, Ireland, May 2000
100. *Psychometric intelligence, personality, and neural correlates of Frequency Accrual Speed Test (FAST) performance*. Invited speaker, Mathematical Cognition Group, Department of Human Communication Science, University College London, UK, February 2000
101. *Psychometric intelligence, personality, and neural correlates of Frequency Accrual Speed Test (FAST) performance*. British Psychophysiology Society 27th Annual Meeting, Institute of Neurology, London, UK, December 1999
102. *Mental speed, intelligence, and personality*. British Psychological Society Annual Conference, Student Group, Belfast, UK, April 1999
103. *Klassische und IRT-Itemanalysen bei Leistungs- und Persönlichkeitstests (Classical test theory and item response theory analyses of ability and personality tests)*. Seminar Aktuelle Probleme psychiatrischer Forschung aus psychologischer Sicht, Psychiatrische Klinik der LMU München, Germany, December 1998
104. *Mental speed, intelligence, and personality*. BAAS Annual Festival of Science, Cardiff, UK, September 1998

Organisation and (Co-)Chairing of Symposia and Workshops

1. *"From Molecules to Mind"*. Tagung experimentell arbeitender Psychologen (TeaP), Heidelberg, Germany, March 2016
2. *"Schizotypie – neue neurobiologische Befunde aus Genetik, Kognition und Bildgebung" ("Schizotypy – new neurobiological findings from genetics, cognition and imaging")*. DGPPN, Berlin, Germany, November 2014
3. *"European Summer School on Eye Movements"*. Freiburg, Germany, September 2014
4. *"Experimentelle und klinische Untersuchungen des Dopamin-Systems" ("Experimental and clinical investigations of the dopamine system")*. AGNP, Munich, Germany, September 2013
5. *"European Summer School on Eye Movements"*. Bonn, Germany, September 2013
6. *"Nicotine as a cognitive enhancer"*. DGPPN, Berlin, Germany, November 2012
7. *"Neuromodulation of Visual Perception"*. Vision Sciences Society, Naples, USA, May 2012
8. *"Cognitive Control: Experimental Psychology and Cognitive Neuroscience"*. TeaP, Mannheim, Germany, April 2012
9. *"Integrating Philosophy and Neuroscience in the Study of Consciousness: How to Make it Work"*. Centre for Advanced Studies, University of Munich, Munich, Germany, December 2011

10. *"Interindividuelle Differenzen von Emotionalität: Neue Befunde aus Genetik und Experimentalpsychologie"* (*"Individual differences in emotionality: new findings from genetics and experimental psychology"*). DPPD Conference, Saarbrücken, Germany, September 2011
11. *"Neuroscientific approaches to personality: from basic research to clinical implications"*. Conference of the International Society for the Study of Individual Differences, London, UK, July 2011
12. *"Neuere Entwicklungen in der Pharmakopsychologie"* (*"New developments in pharmacological psychology"*). Tagung Psychologie & Gehirn, Heidelberg, Germany, June 2011
13. *"The intermediate phenotype strategy in schizophrenia and psychotic bipolar disorder"*. DGPPN, Berlin, Germany, November 2010
14. *"Treatment Effects on Cognition and Brain Function in Schizophrenia"*. DGPPN, Berlin, Germany, November 2010
15. *"Molecular Genetics and Neuroscience II"*. Tagung Psychologie und Gehirn, Greifswald, Germany, June 2010
16. *"Structural and functional imaging of the brain in twins with schizophrenia"*. European Psychiatric Association, Munich, Germany, February 2010
17. *"Neuropsychobiology of inhibitory deficits in schizophrenia: an update"*. 16th European Congress of Psychiatry, Nice, France, April 2008
18. *"Psychopharmakologie und Experimentalpsychologie"* (*"Psychopharmacology and experimental psychology"*). Tagung experimentell arbeitender Psychologen (TeaP), Trier, Germany, March 2007
19. *"Neural correlates of oculomotor control: basic and clinical research"*. Society for Psychophysiological Research, Vancouver, Canada, October 2006
20. *"Experimentalpsychologische Ansätze in der Schizophrenieforschung"* (*"Experimental psychological approaches to the study of schizophrenia"*). Tagung Experimentell Arbeitender Psychologen (TeaP), Mainz, Germany, March 2006
21. *"Augenbewegungen als Indikatoren für Störungen kortikaler Netzwerke bei psychiatrischen Störungen"* (*"Eye movements as indicators of dysfunctional cortical networks in psychiatric disorders"*). Deutsche Gesellschaft für Psychiatrie, Psychotherapie, und Nervenheilkunde Congress, Berlin, Germany, November 2005
22. *"Symposium of the Section of Cognitive Psychopharmacology"*. Institute of Psychiatry, London, UK, April 2001